STRO - Sutro Biopharma

STRO - Sutro Biopharma

https://www.sutrobio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Sutro Biopharma, Inc. ( STRO ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Sutro Biopharma (STRO) delivered earnings and revenue surprises of +64.10% and +293.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

GlobeNewswire • 1 month, 1 week ago • score: 0.28

- On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of ...

Strength Seen in CorMedix ( CRMD ) : Can Its 21.7% Jump Turn into More Strength?

Zacks Commentary • 2 months, 3 weeks ago • score: -0.07

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sutro Biopharma, Inc. ( STRO ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.07

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire • 4 months ago • score: 0.28

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.

52W High

$4.80

52W Low

$0.52

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.58

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

11.78

EV/EBITDA (<8 favorable)

0.41

EV/Revenue (<3 favorable)

0.36

P/S (TTM) (<3 favorable)

0.86

P/B (<3 favorable)

2.11

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.60%

Institutions (25–75% balanced)

62.95%

Shares Outstanding

84,774,000

Float

67,122,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

104,473,000

Gross Profit (TTM)

120,946,000

EPS (TTM)

-2.51

Profit Margin (>10% good)

-2.00%

Operating Margin (TTM) (higher better)

0.24%

ROE (TTM) (>15% strong)

-3.48%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.48

Momentum

Bearish momentum

Value

0.0343

Previous

0.0459

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025